Bronte Capital 将其持有的 Regeneron 股份增加到 $146.57m，持有 12.2%，因为每股收益超出预期，机构所有权上升到 83.31%。 Bronte Capital increased its Regeneron stake to $146.57m, 12.2% holdings, as earning per share surpassed expectations and institutions' ownership rose to 83.31%.
勃朗特资本管理公司在Regeneron制药公司的股份增加到1.4657亿美元,占其股份的12.2%。 Bronte Capital Management has increased its stake in Regeneron Pharmaceuticals to $146.57 million, representing 12.2% of its holdings. 该公司报告,每股收入为11.56美元,超过8.93美元的预期。 The company reported earnings of $11.56 per share, surpassing expectations of $8.93. 一些机构投资者调整了自己的立场,Regeneron现在拥有83.31%的机构。 Several institutional investors have adjusted their positions, with Regeneron now 83.31% owned by institutions. 分析人员提高了库存价格目标,协商一致确定1 109.70美元,反映了强劲的收入增长和积极的市场情绪。 Analysts have raised price targets for the stock, with a consensus of $1,109.70, reflecting strong revenue growth and positive market sentiment.